Clinical Trial Results: Ertugliflozin: Cardioprotective Effects on Epicardial Fat [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial assessing cardioprotective effects of ertugliflozin on epicardial fat in cardiovascular disease/atherosclerosis contexts; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Diseases
• Insulin Resistance
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Stanford University | Conditions: Cardiovascular Diseases, Atherosclerosis | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2026-06-04